| Overview |
| bsm-51681M |
| LIN28B Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Recombinant human LIN28B. |
| Monoclonal |
| K7L3 |
| 0.5ug/ul |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 389421 |
| Q6ZN17 |
| Cytoplasm, Nucleus |
| Lin-28B; LN28B_HUMAN; CSDD 2; CSDD2; FLJ16517; Lin 28 homolog B (C. elegans); Lin 28.2; Lin-28B; Protein lin-28 homolog B. |
| Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth. |
| Application Dilution |
| WB |
=1:500-2000， |
Powered by Bioz